IP Library Granted Patent US 8,278,463
Granted Patent B2
US 8,278,463 · App. 12/418,900 · Granted Oct 2, 2012

Process for the preparation of pure duloxetine hydrochloride

Assignee: Ranbaxy Laboratories Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,463
App. No.
12/418,900
Granted
Oct 2, 2012
Kind
B2
Abstract

The present invention relates to a process for the preparation of pure Duloxetine hydrochloride. The present invention further relates to duloxetine hydrochloride substantially free of residual hydrochloric acid.

Claims (9)

1. A process for the preparation of pure duloxetine hydrochloride, comprising the steps of

a) treating duloxetine free base with hydrochloric acid in the presence of an organic solvent to obtain duloxetine hydrochloride,

b) isolating the duloxetine hydrochloride from the reaction mixture of step a),

c) washing the isolated duloxetine hydrochloride from step b) with an organic solvent till the pH of the filtrate is in the range of about 5 to about 6, and

d) drying the duloxetine hydrochloride obtained in step c) to obtain pure duloxetine hydrochloride,

wherein the pure duloxetine hydrochloride obtained in step d) has a chloride content of not more than 10.7% w/w.

2. A process according to claim 1 , wherein the hydrochloric acid is used in equimolar quantities with respect to the molar quantity of duloxetine or in slight excess.

3. A process according to claim 1 , wherein the washing is performed by passing the organic solvent through duloxetine hydrochloride, by slurrying the duloxetine hydrochloride in the organic solvent or by a combination thereof.

4. A process according to claim 1 , wherein the pure duloxetine hydrochloride obtained in step d) contains 4-[3-(methylamino)-1-thiophen-2-ylpropyl]naphthalen-1-ol of Formula II of about 0.1% w/w or less

Assignments (2)
MERGER Recorded Jan 13, 2016
From: RANBAXY LABORATORIES LIMTED
To: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Reel/Frame 037513/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2009
From: BISWAS, SUJOY; KARANJAI, KEYA
To: RANBAXY LABORATORIES LIMITED
Reel/Frame 023128/0129 →
Priority Claims (1)
IN 903/DEL/2008 · Apr 4, 2008 · national
Continuity (1)
Related Publication 20090275760A1 · Nov 5, 2009